E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia.
Siba El Hussein,Keyur P. Patel,Hong Fang,Beenu Thakral,Sanam Loghavi,Rashmi Kanagal-Shamanna,Sergej Konoplev,Elias Jabbour,L. Jeffrey Medeiros,Joseph D. Khoury +9 more
TL;DR: Neoplastic cells in ANKL are commonly positive for c-MYC and EBER, and they have a high frequency of p53 overexpression, frequently with corresponding TP53 mutations.
Journal ArticleDOI
Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Guillaume Richard-Carpentier,Hagop M. Kantarjian,Nicholas J. Short,Farhad Ravandi,Alessandra Ferrajoli,Heather M Schroeder,Guillermo Garcia-Manero,Guillermo Montalban Bravo,Jorge E. Cortes,Monica Kwari,Christopher Loiselle,Rebecca Garris,Nicole Volter,Nitin Jain,Marina Konopleva,Koichi Takahashi,Koji Sasaki,William G. Wierda,Elias Jabbour +18 more
TL;DR: The primary outcome is relapse-free survival (RFS) and secondary outcomes include CR rates, MRD negativity (MRD-) rates and overall survival (OS).
Journal ArticleDOI
Long-term results of frontline dasatinib in chronic myeloid leukemia
Abhishek Maiti,Jorge E. Cortes,Keyur P. Patel,Lucia Masarova,Gautam Borthakur,Farhad Ravandi,Srdan Verstovsek,Alessandra Ferrajoli,Zeev Estrov,Guillermo Garcia-Manero,Tapan M. Kadia,Graciela M. Nogueras-Gonzalez,Jeffrey Skinner,Rebecca Poku,Sara Dellasala,Rajyalakshmi Luthra,Elias Jabbour,Susan O'Brien,Hagop M. Kantarjian +18 more
TL;DR: The authors report the long‐term follow-up from the first study using dasatinib as initial therapy for chronic‐phase chronic myeloid leukemia, which found more and faster cytogenetic and molecular responses compared with imatinib.
Journal ArticleDOI
A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy
Guillermo Garcia-Manero,Elias Jabbour,Marina Konopleva,Naval Daver,Gautam Borthakur,Courtney D. DiNardo,Prithviraj Bose,Parita Patel,Rami S. Komrokji,Aditi Shastri,Gail J. Roboz,Robert Miller,Sarah Arbe-Barnes,Mary M. Reilly,Peter McGuirk,Tara Kearney,Brian Keogh,Hagop M. Kantarjian +17 more
TL;DR: The data indicate that Tomaralimab is a potential therapy for low risk/Int-1 MDS patients with low or Int-1 risk MDS after failure with prior therapy with HMA, and the toxicity, pharmacokinetic profile, receptor occupancy, cytokine profile, as well as a novel set of TLR2 related genes.
Journal ArticleDOI
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
Nitin Jain,Abhishek Maiti,Farhad Ravandi,Marina Konopleva,Naval Daver,Tapan M. Kadia,Naveen Pemmaraju,Nicholas J. Short,Partow Kebriaei,Jing Ning,Jorge E. Cortes,Elias Jabbour,Hagop M. Kantarjian +12 more
TL;DR: In this paper, the authors designed a phase 1/2 study combining inotuzumab ozogamicin with bosutinib for this patient population, and the primary objective was to determine the safety and the maximum tolerated dose (MTD).